SPRED1 and acute myeloid leukemia: We next divided the AML patients into young (age < 35), middle (35 ≤ age < 60) and old (age ≥ 60) groups and found there was no significant difference of SPRED1 mRNA expression among these groups (p > 0.05; Figure 1B).